These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15319398)

  • 21. A natural history model of stage progression applied to breast cancer.
    Plevritis SK; Salzman P; Sigal BM; Glynn PW
    Stat Med; 2007 Feb; 26(3):581-95. PubMed ID: 16598706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mathematical modelling of tumour acidity.
    Smallbone K; Gatenby RA; Maini PK
    J Theor Biol; 2008 Nov; 255(1):106-12. PubMed ID: 18725231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
    Azzaroli F; Colecchia A; Lodato F; Trerè D; Bacchi Reggiani ML; Festi D; Prati GM; Accogli E; Casanova S; Derenzini M; Roda E; Mazzella G
    Aliment Pharmacol Ther; 2006 Jul; 24(1):129-36. PubMed ID: 16803611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The microenvironments of multistage carcinogenesis.
    Laconi E; Doratiotto S; Vineis P
    Semin Cancer Biol; 2008 Oct; 18(5):322-9. PubMed ID: 18456510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A stochastic model for predicting the mortality of breast cancer.
    Lee S; Zelen M
    J Natl Cancer Inst Monogr; 2006; (36):79-86. PubMed ID: 17032897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer progression and survival in BRCA2 mutation carriers.
    Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
    J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An ordinary differential equation model for the multistep transformation to cancer.
    Spencer SL; Berryman MJ; García JA; Abbott D
    J Theor Biol; 2004 Dec; 231(4):515-24. PubMed ID: 15488528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.
    Bodmer D; Ligtenberg MJ; van der Hout AH; Gloudemans S; Ansink K; Oosterwijk JC; Hoogerbrugge N
    Br J Cancer; 2006 Sep; 95(6):757-62. PubMed ID: 16909138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian modeling of multiple lesion onset and growth from interval-censored data.
    Dunson DB; Holloman C; Calder C; Gunn LH
    Biometrics; 2004 Sep; 60(3):676-83. PubMed ID: 15339290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
    Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
    Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Invited commentary: Challenges of using contact data to understand acute respiratory disease transmission.
    Halloran ME
    Am J Epidemiol; 2006 Nov; 164(10):945-6. PubMed ID: 16968867
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessing BRCA carrier probabilities in extended families.
    Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
    J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of mammography on U.S. breast cancer mortality, 1975-2000: are intermediate outcome measures informative?
    Habbema JD; Tan SY; Cronin KA
    J Natl Cancer Inst Monogr; 2006; (36):105-11. PubMed ID: 17032900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-period-cohort models for the Lexis diagram.
    Carstensen B
    Stat Med; 2007 Jul; 26(15):3018-45. PubMed ID: 17177166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Estimation of the future epidemiological situation of tuberculosis in Japan].
    Ohmori M; Yoshiyama T; Ishikawa N
    Kekkaku; 2008 Apr; 83(4):365-77. PubMed ID: 18516900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A regression model with unexplained residuals was preferred in the analysis of the fetal origins of adult diseases hypothesis.
    Keijzer-Veen MG; Euser AM; van Montfoort N; Dekker FW; Vandenbroucke JP; Van Houwelingen HC
    J Clin Epidemiol; 2005 Dec; 58(12):1320-4. PubMed ID: 16291478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-1 receptor antagonist gene polymorphism in human colorectal cancer.
    Viet HT; Wågsäter D; Hugander A; Dimberg J
    Oncol Rep; 2005 Oct; 14(4):915-8. PubMed ID: 16142351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
    Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
    Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.